Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Innate and myeloid checkpoint antibodies act on macrophages, natural killer (NK) cells and other innate immune cells. Magrolimab blocks CD47, which binds signal-regulatory protein alpha (SIRPĪ±) on macrophages and suppresses phagocytosis of target cells. Monalizumab targets the inhibitory NK cell receptor NKG2A, which recognizes HLA-E on tumor cells. Axatilimab and cabiralizumab bind colony-stimulating factor 1 receptor (CSF1R) and are used to study tumor-associated macrophages in vitro and in vivo. Further antibodies target sialic acid-binding Ig-like lectins (Siglecs), TREM receptors and the activating receptor NKG2D.
Tesnatilimab is a human IgG4 monoclonal antibody designed to target the immune activating receptor NKG2D. It exhibits potential immunomodulatory and anti-inflammatory properties. This antibody is particularly useful for research in inflammatory bowel disease (IBD), providing a valuable tool for understanding disease mechanisms and developing therapeutic strategies.
Synonyms: SNDX-6352
Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody designed to selectively bind with high affinity to colony-stimulating factor 1 receptor (CSF-1R). This antibody is primarily utilized in research focused on chronic graft versus host disease (cGVHD) and various neoplastic diseases, providing a valuable tool for studies aimed at elucidating the role of CSF-1R in these complex conditions.
Spevatamig is a bispecific antibody of the (H-Ī³1_L-Īŗ)_(H-Ī³1_L-Īŗ) type, designed to target CD47 and CLDN18. This dual specificity facilitates its application in the selective targeting and inhibition of pathways crucial in cancer cell survival and immune evasion, making it a valuable tool for research in oncology and immunotherapy.
PY314 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the Triggering Receptor Expressed on Myeloid cells 2 (TREM2). This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended.
LY3022855 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CSF1R (Colony Stimulating Factor 1 Receptor), also known as M-CSFR or CD115. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.
Peluntamig is a bispecific antibody of the H-Ī³1_L-Īŗ type that targets both CD47 and DLL3. This dual specificity allows for enhanced therapeutic potential in oncology research, leveraging the roles of CD47 in "don't eat me" signal inhibition and DLL3 in cancer stem cell signaling pathways.
The Anti-Siglec-15/CD33L3 Antibody is derived from human sources and expressed in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets Siglec-15, also known as CD33L3, a sialic acid-binding Ig-like lectin involved in immune regulation. Comprising a human IgG1 heavy chain and a human lambda light chain, this antibody has a predicted molecular weight of 146.02 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa. This product is essential for research focusing on the role of Siglec-15 in immune responses and its potential implications in therapeutic interventions.
BI-765063 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting SIRPĪ± (CD172a). This antibody is comprised of an IgG4PE heavy chain and a human kappa (huĪŗ) light chain, with a predicted molecular weight of 144.36 kDa. For experimental control purposes, Human IgG4 kappa, Isotype Control is recommended. This antibody is suitable for a variety of research applications focusing on the modulation and study of SIRPĪ±-mediated signaling pathways.
The Anti-CSF1R/CD115 Antibody (2-4A5-4) is a chimeric monoclonal antibody derived from rat IgG1, Īŗ, specifically designed to target human CSF1R/CD115. This antibody is ideal for investigating the biological functions and signaling pathways mediated by CSF1R/CD115. For accurate isotype control in experiments, it is recommended to use the Rat IgG1 kappa Isotype Control, ensuring specificity and consistency in antibody performance.
Aldastotug is a human monoclonal antibody of the IgG1Īŗ isotype designed to specifically target SIGLEC15. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.
CC-90002 is a humanized monoclonal antibody targeting CD47 with high specificity and subnanomolar affinity, evidenced by its dissociation constant (Kd). This antibody is designed for advanced studies in both hematologic malignancies and solid tumors, providing a critical tool for research in cancer therapy mechanisms and potential therapeutic interventions.
Suvonstobart is a monoclonal antibody that specifically targets human CD24, a signal transducer integral to various immune cell signaling pathways. By binding to CD24, Suvonstobart activates these pathways, demonstrating both immunostimulatory and antitumor properties. This antibody is utilized primarily in research focused on cancer immunotherapy and the modulation of immune responses.
Synonyms: AK 117
Ligufalimab (AK 117) is a humanized IgG4 monoclonal antibody targeting CD47. This antibody is engineered to avoid the induction of red blood cell (RBC) hemaglutination, while effectively promoting phagocytosis. Ligufalimab has demonstrated significant anti-tumor activity in various models, making it a valuable tool for research in cancer immunotherapy.
Synonyms: Hu5F9-G4
Magrolimab (Hu5F9-G4) is a humanized monoclonal antibody targeting CD47. By inhibiting the CD47-mediated "don't eat me" signal, Magrolimab enhances macrophage-mediated phagocytosis. This antibody demonstrates significant antitumor activity, particularly in the treatment of malignant bone tumors and breast cancer, making it a valuable tool for research in oncology and immunotherapy.
PY159 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting TREM1 (Triggering Receptor Expressed on Myeloid cells 1), also known as CD354. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 143.66 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.
The Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody specifically designed to target TREM2, a receptor expressed on microglia and involved in the regulation of inflammatory processes. For accurate experimental control, it is recommended to use Human IgG1 kappa as an isotype control. This antibody is ideal for research applications investigating the role of TREM2 in neuroinflammation and other related pathological conditions.
Synonyms: NCI m971
Anti-Siglec-2 / CD22 (NCI m971) is a humanized monoclonal antibody specifically designed to target CD22, a member of the Siglec family of lectins predominantly expressed on B cells. This antibody is utilized in the therapeutic management of acute lymphoblastic leukemia (ALL), offering a targeted approach to treatment by binding to the CD22 antigen, thereby modulating immune response and B cell activity.
Synonyms: TJ011133; TJC4
Lemzoparlimab (TJ011133; TJC4) is a humanized IgG4 monoclonal antibody targeting CD47. This antibody exhibits potent antitumor activity, making it a valuable tool for research in cancer immunotherapy. Lemzoparlimab functions by engaging with the CD47 protein, a key regulator in the 'don't eat me' signal that protects cancer cells from macrophage-mediated phagocytosis. By blocking this signal, Lemzoparlimab promotes the phagocytosis of malignant cells, thereby facilitating an immune response against the tumor. This mechanism highlights its potential utility in studies focused on tumor immunity and therapeutic antibody development.
Out of stock
All 3 sizes
The Anti-CD47 Antibody (B6.H12) is a mouse monoclonal IgG1, Īŗ antibody engineered to target human CD47. This antibody is designed for specificity to CD47, a critical regulator in the 'don't eat me' signal which inhibits phagocytosis, making it a vital tool in cancer immunotherapy research. For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control in conjunction with this antibody to ensure specificity and consistency in results.
AK-001 is a fully human monoclonal antibody of the IgG1 subclass, specifically targeting Siglec-8. This antibody is designed for research applications, including the study of chronic rhinosinusitis with nasal polyps. For appropriate experimental controls, researchers should use Human IgG1 kappa as the isotype control when working with AK-001.
Isuventatug is a monoclonal antibody engineered to specifically bind to human MHC class I chain-related molecules A and B (MICA and MICB). By targeting these molecules, Isuventatug modulates the interactions between immune cells and tumor cells, thereby exerting antitumor effects. This antibody is particularly valuable in the study of cancer immunotherapy, providing a promising tool for researchers exploring innovative treatments in oncology.
AB-25E9 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Siglec-15, also known as CD33L3. This antibody has a predicted molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. AB-25E9 is designed for use in various immunological assays to study the role of Siglec-15 in immune regulation and its potential implications in therapeutic interventions.
Synonyms: MCS110
Lacnotuzumab (MCS110) is a humanized IgG1/Īŗ monoclonal antibody that selectively targets colony-stimulating factor 1 (CSF-1), effectively blocking its interaction with the CSF-1 receptor (CSF-1R). This neutralization impedes CSF-1R activation, which is crucial in various cellular processes. Lacnotuzumab is primarily utilized in research focused on pigmented villonodular synovitis, providing valuable insights into the pathophysiology and potential therapeutic targets of this disease.
Synonyms: AK002; Antolimab
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody specifically designed to target sialic acid-binding Ig-like lectin 8 (SIGLEC8). This antibody promotes apoptosis in interleukin-5 (IL-5)-activated eosinophils and effectively inhibits immunoglobulin E (IgE)-mediated mast cell activation. Lirentelimab is primarily utilized in research focused on eosinophilic gastritis and duodenitis, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for these conditions.
Synonyms: IPH2201
Monalizumab (IPH2201) is a humanized monoclonal antibody designed to inhibit the immune checkpoint receptor Natural Killer Group 2A (NKG2A). By blocking NKG2A, Monalizumab enhances interferon-gamma (IFN-Ī³) production, which in turn augments the effector functions of natural killer (NK) cells. This antibody is primarily utilized in research focused on understanding and treating head and neck squamous cell carcinoma (HNSCC).
